Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche has acquired privately held biopharmaceutical company Therapeutic Human Polyclonals for $56.5 million in order to build on its antibody research.
Subscribe to our email newsletter
<p>THP, a California-based company with a subsidiary in Germany, is focused on research in human antibody technologies. The company has developed a unique transgenic mammalian platform to create human antibodies. The technology will enable the generation of both monoclonal and polyclonal antibody therapeutics with enhanced efficacy. <br /><br />Roche has a strong pipeline of therapeutic antibodies with its cancer therapies MabThera, Herceptin and Avastin. Roche plans to fully integrate THP into the Roche Pharma Center of Excellence for Protein Research organization in Germany. <br /><br />THP was founded to develop and commercialize next-generation human antibody therapies with initial funding and incubation from Research Corporation Technologies. In 2002, SangStat Medical Corp joined RCT in continuing to fund development of THP's antibody platform.</p>